mPredict Co-crystal Prediction Service

mPredict Co-crystal Prediction Service is an Artificial Intelligence and computational chemistry-based screening service to predict optimum co-formers for co-crystallization of the API. Co-crystallization is an important API Processing strategy for solubility limited compounds and is useful for substances without an ionizable functional group as opposed to salt formation. But it is challenging to find a co-former as several screening experiments using different screening techniques need to be performed. During initial drug development stages, very limited API material is available, and it is expensive. For generic companies, the time pressure severely limits an all-round characterization for co-crystals. mPredict enables quick formulation decisions to bring therapies faster to patients and helps saves time. It helps find optimal co-formers 3X faster than random digital screening and 96% faster than experimental screening. Additionally, it saves resources as the actual drug substance is not required for screening. mPredict is 2X more reliable and accurate than industry standard and alternative solutions. With pharmaceutical customers getting computational predictions in less than 5 days, we have a fast turnaround and straightforward execution. mPredict has been developed fully internally on the main pillar of maintaining data quality by training the tool on consistent high-quality experimental data covering broad chemical space using smart iterative approaches like clustering and active learning. We followed standard data science practices by maintaining highest standards for security and confidentiality by creating an environment that is adhering to all relevant internal SOPs for data processing and IT infrastructure

After launch, we received great interest from the market and leading pharmaceutical companies with whom we plan to collaborate extensively.